A Recombinant Vaccine of H5N1 HA1 Fused with Foldon and Human IgG Fc Induced Complete Cross-Clade Protection against Divergent H5N1 Viruses
2011

A Recombinant Vaccine of H5N1 HA1 Induces Cross-Clade Protection

Sample size: 45 publication 10 minutes Evidence: high

Author Information

Author(s): Du Lanying, Leung Virtual Ho-Chuen, Zhang Xiujuan, Zhou Jie, Chen Min, He Wu, Zhang Hai-Ying, Chan Chris C. S., Poon Vincent Kwok-Man, Zhao Guangyu, Sun Shihui, Cai Lifeng, Zhou Yusen, Zheng Bo-Jian, Jiang Shibo

Primary Institution: Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, United States of America

Hypothesis

Can recombinant influenza vaccines provide cross-protection against divergent strains of H5N1 virus?

Conclusion

The study found that the recombinant vaccines induced strong immune responses and provided complete cross-clade protection against various H5N1 strains in mice.

Supporting Evidence

  • The vaccines induced strong immune responses in vaccinated mice.
  • Both vaccine candidates provided complete cross-clade protection against lethal challenges.
  • Immunization with HA1-Fdc resulted in higher neutralizing antibody titers compared to HA1-Fc.
  • Vaccinated mice showed significantly lower viral loads in lung tissues after challenge.

Takeaway

Scientists created a new vaccine that helps protect mice from different types of a dangerous bird flu virus.

Methodology

The study involved designing two recombinant vaccines, HA1-Fc and HA1-Fdc, and testing their immune responses and protection in a mouse model.

Limitations

The study was conducted in mice, and results may not directly translate to humans.

Participant Demographics

Female BALB/c mice aged 6–8 weeks were used in the study.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0016555

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication